Four-year outcomes after intravitreal aflibercept for macular neovascularization in patients with pathologic myopia.

IF 2.3 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2024-11-20 DOI:10.1097/IAE.0000000000004341

Yuka Mizuno-Onishi, Tae Igarashi, Kengo Uramoto, Yuichiro Kaneko, Natsuko Nagaoka, Takeshi Yoshida, Kyoko Ohno-Matsui

{"title":"Four-year outcomes after intravitreal aflibercept for macular neovascularization in patients with pathologic myopia.","authors":"Yuka Mizuno-Onishi, Tae Igarashi, Kengo Uramoto, Yuichiro Kaneko, Natsuko Nagaoka, Takeshi Yoshida, Kyoko Ohno-Matsui","doi":"10.1097/IAE.0000000000004341","DOIUrl":null,"url":null,"abstract":"Purpose: The natural course of the visual acuity in eyes with myopic macular neovascularization (myopic MNV) is poor. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have demonstrated safety and efficacy in the short-term for managing myopic MNV. The purpose of this study was to determine the 4-year outcomes of intravitreal aflibercept (IVA) injections.Method: A retrospective monocentric study including 49 eyes of 48 patients diagnosed with myopic MNV. These patients underwent treatment with IVA using the pro re nata (PRN) regimen after the first injection. The minimum follow-up duration was 4 years.Results: The patients had an average age of 63.8 years and an average axial length of 29.7 mm. The mean number of IVA injections was 1.6, and 30 eyes (61.2%) had a single injection. At the baseline and at 1-, 2-, 3-, and 4-years, the mean best-corrected visual acuities (BCVAs) were 20/45, 20/41, 20/43, 20/51, and 20/53, respectively. The differences in the BCVA at the different times from that at the baseline were not significant.Conclusion: IVA therapy with the PRN regimen provides a 4-year visual benefit in eyes with myopic MNV, and it is better than the reported natural course in maintaining the BCVA.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004341","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The natural course of the visual acuity in eyes with myopic macular neovascularization (myopic MNV) is poor. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have demonstrated safety and efficacy in the short-term for managing myopic MNV. The purpose of this study was to determine the 4-year outcomes of intravitreal aflibercept (IVA) injections.

Method: A retrospective monocentric study including 49 eyes of 48 patients diagnosed with myopic MNV. These patients underwent treatment with IVA using the pro re nata (PRN) regimen after the first injection. The minimum follow-up duration was 4 years.

Results: The patients had an average age of 63.8 years and an average axial length of 29.7 mm. The mean number of IVA injections was 1.6, and 30 eyes (61.2%) had a single injection. At the baseline and at 1-, 2-, 3-, and 4-years, the mean best-corrected visual acuities (BCVAs) were 20/45, 20/41, 20/43, 20/51, and 20/53, respectively. The differences in the BCVA at the different times from that at the baseline were not significant.

Conclusion: IVA therapy with the PRN regimen provides a 4-year visual benefit in eyes with myopic MNV, and it is better than the reported natural course in maintaining the BCVA.

查看原文本刊更多论文

病理性近视患者静脉注射阿弗利贝赛普治疗黄斑新生血管后的四年疗效。

目的：近视性黄斑新生血管（近视性 MNV）患者的自然视力很差。抗血管内皮生长因子（VEGF）药物的玻璃体内注射在短期内治疗近视性黄斑新生血管方面具有安全性和有效性。本研究旨在确定玻璃体内注射阿弗利百普（IVA）的四年疗效：方法：这是一项回顾性单中心研究，包括48名确诊为近视MNV患者的49只眼睛。这些患者在首次注射后，采用PRN方案接受了IVA治疗。随访时间最短为 4 年：患者的平均年龄为 63.8 岁，平均轴长为 29.7 毫米。平均 IVA 注射次数为 1.6 次，30 只眼睛（61.2%）只进行了一次注射。在基线和 1、2、3、4 年时，最佳矫正视力（BCVA）的平均值分别为 20/45、20/41、20/43、20/51 和 20/53。不同时间的最佳矫正视力与基线时的最佳矫正视力差异不大：结论：采用 PRN 方案进行 IVA 治疗可为近视 MNV 患者带来 4 年的视力收益，在维持 BCVA 方面优于报告的自然疗程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.